Current knowledge on assessing the effects of and managing bleeding and urgent procedures with direct oral anticoagulants

American Journal of Health-System Pharmacy

Volumn 73, Issue 10, 2016, Pages S14-S26

  Dager, William ^a   Hellwig, Thaddaus ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SOUTH DAKOTA STATE UNIVERSITY   (United States)

^c USD Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 8 INHIBITOR; DABIGATRAN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BLOOD TRANSFUSION; CEREBROVASCULAR ACCIDENT; HUMAN; PRIORITY JOURNAL; SECONDARY PREVENTION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; AMBULATORY CARE; CHEMICALLY INDUCED; HEMORRHAGE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AMBULATORY CARE; ANTICOAGULANTS; ANTITHROMBINS; DABIGATRAN; FACTOR XA INHIBITORS; HEMORRHAGE; HUMANS;

EID: 84968733042     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp150960     Document Type: Article

References (108)

1. Dossett LA, Riesel JN, Griffin MR, Cotton BA. Prevalence and implications of preinjury warfarin use: an analysis of the National Trauma Databank. Arch Surg. 2011; 146:565-70.
2. Kirley K, Qato DM, Kornfield R et al. National trends in oral anticoagulant use in the United States, 007 to 2011. Circ Cardiovasc Qual Outcomes. 2012; 5:615-21.
3. Caldeira D, Barra M, Pinto FJ et al. Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis. J Neurol. 2015; 262:516-22.
4. Cameron C, Coyle D, Richter T et al. Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding n patients with atrial fibrillation. BMJ Open. 2014; 4:e004301.
5. Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani DJ. New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol. 2013; 70:1486-90.
6. Gomez-Outes A, Lecumberri R, Suarez-Gea ML et al. Case fatality rates of recurrent thromboembolism and bleeding in patients receiving direct oral anticoagulants for the initial and extended treatment of venous thromboembolism: a systematic review. J Cardiovasc Pharmacol Ther. 2015; 20:490-500.
7. Sardar P, Chatterjee S, Lavie CJ et al. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials. Int J Cardiol. 2015; 179:279-87.
8. Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost. 2015; 113:931-42.
9. Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology. 2013; 145:105-12.e15.
10. Loffredo L, Perri L, Violi F. Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: a meta-analysis of interventional trials. Dig Liver Dis. 2015; 47:429-31.
11. Chan KE, Edelman ER, Wenger JB et al. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation. 2015; 131:972-9.
12. Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369:799-808.
13. Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363:2499-510.
14. Büller HR, Prins MH, Lensin AW et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366:1287-97.
15. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in atients with atrial fibrillation. N Engl J Med. 2009; 361:1139-51.
16. Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369:2093-104.
17. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365:981-92.
18. Hokusai VT, Buller HR, Decousus H et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369:1406-15.
19. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365:883-91.
20. Schulman S, Kakkar AK, Goldhaber SZ et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014; 129:764-72.
21. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361:2342-52.
22. Nutescu EA, Dager WE, Kalus JS et al. Management of bleeding and reversal strategies for oral anticoagulants: clinical practice considerations. Am J Health-Syst Pharm. 2013; 70:1914-29.
23. Manchikanti L, Falco FJ, Benyamin RM et al. Assessment of bleeding risk of interventional techniques: a best evidence synthesis of practice patterns and perioperative management of anticoagulant and antithrombotic therapy. Pain Physician. 2013; 16(suppl):SE261-318.
24. Narouze S, Benzon HT, Provenzano DA et al. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med. 2015; 40:182-212.
25. Avecilla ST, Ferrell C, Chandler WL, Reyes M. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol. 2012; 137:572-4.
26. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010; 104:1263-71.
27. Dager WE, Gosselin RC, Kitchen S, Dwyre D. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study. Ann Pharmacother. 2012; 46:1627-36.
28. Lindahl TL, Baghaei F, Blixter IF et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost. 2011; 105:371-8.
29. Miyares MA, Davis K. Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health-Syst Pharm. 2012; 69:1473-84.
30. Mueck W, Lensing AW, Agnelli G et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011; 50:675-86.
31. Ogata K, Mendell-Harary J, Tachibana M et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010; 50:743-53.
32. Samama MM, Martinoli JL, LeFlem L et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost. 2010; 103:815-25.
33. Stangier J, Rathgen K, Stähle H et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007; 64:292-303.
34. Wong PC, Crain EJ, Xin B et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008; 6:820-9.
35. Cuker A, Husseinzadeh H. Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. J Thromb Thrombolysis. 2015; 39:288-94.
36. van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care NR results in patients treated with dabigatran. Am J Med. 2012; 125:417-20.
37. Asmis LM, Alberio L, Angelillo-Scherrer A et al. Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res. 2012; 129:492-8.
38. Becker RC, Yang H, Barrett Y et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis. 2011; 32:183-7.
39. Baumann Kreuziger LM, Keenan JC, Morton CT, Dries DJ. Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates. Biomed Res Int. 2014; 2014:583794.
40. Garber ST, Sivakumar W, Schmidt RH. Neurosurgical complications of direct thrombin inhibitors-catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. J Neurosurg. 2012; 116:1093-6.
41. Harinstein LM, Morgan JW, Russo N. Treatment of dabigatran-associated bleeding: case report and review of the literature. J Pharm Pract. 2013; 26:264-9.
42. Hoffman M, Volovyk Z, Monroe DM. Reversal of dabigatran effects in models of thrombin generation and hemostasis by factor VIIa and prothrombin complex concentrate. Anesthesiology. 2015; 122:353-62.
43. Htun KT, McFadyen J, Tran HA. The successful management of dabigatran-associated critical endorgan bleeding with recombinant factor VIIa. Ann Hematol. 2014; 93:1785-6.
44. Kumar R, Smith RE, Henry BL. A review of and recommendations for the management of patients with lifethreatening dabigatran-associated hemorrhage: a single-center university hospital experience. J Intensive Care Med. 2015; 30:462-72.
45. Lazo-Langner A, Lang ES, Douketis J. Clinical review: clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications. Crit Care. 2013; 17:230.
46. Maddry JK, Amir MK, Sessions D, Heard K. Fatal dabigatran toxicity secondary to acute renal failure. Am J Emerg Med. 2013; 31:462.e1-2.
47. Marlu R, Hodaj E, Paris A et al. Effect of non-specific reversal gents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012; 108:217-24.
48. Ross B, Miller MA, Ditch K, Tran M. Clinical experience of lifethreatening dabigatran-related bleeding at a large, tertiary care, academic medical center: a case series. J Med Toxicol. 2014; 10:223-8.
49. Solbeck S, Nilsson CU, Engstrom M et al. Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study. Scand J Clin Lab Invest. 2014; 74:591-8.
50. Truumees E, Gaudu T, Dieterichs C et al. Epidural hematoma and intraoperative hemorrhage in a spine trauma patient on Pradaxa (dabigatran). Spine. 2012; 37:E863-5.
51. Lindahl TL, Wallstedt M, Gustafsson KM et al. More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate. Thromb Res. 2015; 135:544-7.
52. CSL Behring LLC. Kcentra (prothrombin complex concentrate): highlights of prescribing information. http://labeling.cslbehring. com/PI/US/Kcentra/EN/Kcentra-Prescribing-Information.pdf (accessed 2016 Jan 15).
53. Baxter International. FEIBA (antiinhibitor coagulant complex) prescribing information. http:// feiba.com/pdf/FEIBA-SPC.pdf (accessed 2015 Sep 09).
54. Institute for Safe Medication Practices. ISMP quarterly action agenda. Safety brief: confusion a "factor" with "PCC" orders. www. ismp.org/newsletters/acutecare/ articles/ActionAgenda1304.doc (accessed 2015 Aug 12).
55. Eerenberg ES, Kamphuisen PW, Sijpkens MK et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011; 124:1573-9.
56. Khoo TL, Weatherburn C, Kershaw G et al. The use of FEIBA in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol. 2013; 35:222-4.
57. Diaz MQ, Borobia AM, Nunez MA et al. Use of prothrombin complex concentrates for urgent reversal f dabigatran in the emergency department. Haematologica. 2013; 98:e143-4.
58. Wychowski MK, Kouides PA. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother. 2012; 46:e10.
59. Cano EL, Miyares MA. Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. Am J Geriatr Pharmacother. 2012; 10:160-3.
60. Dumkow LE, Voss JR, Peters M, Jennings DL. Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma. Am J Health-Syst Pharm. 2012; 69:1646-50.
61. Kamboj J, Kottalgi M, Cirra VR et al. Direct thrombin inhibitors: a case indicating benefit from 'plasmapheresis' in toxicity: a call for establishing "guidelines" in overdose and to find an "antidote"! Am J Ther. 2012; 19:e182-5.
62. Honickel M, Treutler S, van Ryn J et al. Reversal of dabigatran anticoagulation ex vivo: porcine study comparing prothrombin complex concentrates and idarucizumab. Thromb Haemost. 2015; 113:728-40.
63. Dager WE, Gosselin RC, Roberts AJ. Reversing dabigatran in lifethreatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med. 2013; 41:e42-6.
64. Faust AC, Peterson EJ. Management of dabigatran-associated intracerebral and intraventricular hemorrhage: a case report. J Emerg Med. 2014; 46:525-9.
65. Schulman S, Ritchie B, Goy JK et al. Activated prothrombin complex concentrate for dabigatranassociated bleeding. Br J Haematol. 2014; 164:308-10.
66. Honickel M, Maron B, van Ryn J et al. Therapy with activated prothrombin complex concentrate is effective in reducing dabigatranassociated blood loss in a porcine polytrauma model. Thromb Haemost. 2016; 115:271-84.
67. Dibu JR, Weimer JM, Ahrens C et al. The role of FEIBA in reversing novel oral anticoagulants in intracerebral hemorrhage. Neurocrit Care. Epub ahead of print. 2015 ov 6.
68. Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am J Kidney Dis. 2013; 61:487-9.
69. Dager WE, Roberts AJ, Gosselin R, White R. Low dose FEIBA and hemodialysis for managing major bleeding on dabigatran. J Thromb Haemost. 2015; 13:881-2. Abstract.
70. Guy S, Kitchen S, Laidlaw S et al. The use of ecarin chromogenic assay and prothrombinase induced clotting time in the monitoring of lepirudin for the treatment of heparin-induced thrombocytopenia. Br J Haematol. 2008; 142:466-8.
71. Love JE, Ferrell C, Chandler WL. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost. 2007; 98:234-42.
72. Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med. 2011; 49:761-72.
73. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012; 23:138-43.
74. Bouchard J, Ghannoum M, Bernier-Jean A et al. Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. Clin Toxicol. 2015; 53:156-63.
75. Claisse G, Delavenne X, Masson I et al. Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit. Clin Kidney J. 2015; 8:199-201.
76. Getta B, Muller N, Motum P et al. Intermittent haemodialysis and continuous veno-venous dialysis are effective in mitigating major bleeding due to dabigatran. Br J Haematol. 2015; 169:603-4.
77. Paul S, Hamouda D, Prashar R et al. Management of dabigatraninduced bleeding with continuous venovenous hemodialysis. Int J Hematol. 2015; 101:594-7.
78. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an openlabel, parallel-group, single-centre study. Clin Pharmacokinet. 2010; 49:259-68.
79. Khadzhynov D, Wagner F, Formella S et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost. 2013; 109:596-605.
80. Lowe MP, Collins J, Yehia M, Eaddy N. Reversal of dabigatran with haemodialysis n a patient requiring decompression for cord compression from an epidural abscess. Nephrology. 2013; 18:580-2.
81. Singh T, Maw TT, Henry BL et al. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clin J Am Soc Nephrol. 2013; 8:1533-9.
82. Wanek MR, Horn ET, Elapavaluru S et al. Safe use of hemodialysis for dabigatran removal before cardiac surgery. Ann Pharmacother. 2012; 46:e21.
83. Chiew AL, Khamoudes D, Chan BS. Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. Clin Toxicol. 2014; 52:283-7.
84. Herzog E, Kaspereit F, Krege W et al. Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage. J Thromb Haemost. 2015; 13:2220-6.
85. Siegal DM. Managing targetspecific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis. 2015; 39:395-402.
86. Perlstein I, Wang Z, Song Y et al. Reversal of apixaban anticoagulation by 4-factor prothrombin complex concentrates in healthy subjects. https://ash.confex.com/ash/2014/ webprogram/Paper74345.html (accessed 2016 Feb 18).
87. Cheung YW, Barco S, Hutten BA et al. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers. J Thromb Haemost. 2015; 13:1799-805.
88. Levi M, Moore KT, Castillejos CF et al. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost. 2014; 12:1428-36.
89. Schultz N, Tran HTT, Henriksson C et al. Reversing the effect of rivaroxaban - an in-vitro study. J Thromb Haemost. 2015; 13:216. Abstract
90. Dager WE, Roberts AJ, Gosselin R, White R. Effective use of low dose activated prothrombin complex concentrates in managing major GI bleeding on rivaroxaban. J Thromb Haemost. 2015; 13:882. bstract.
91. Grandhi R, Newman WC, Zhang X et al. Administration of 4-factor prothrombin complex concentrate as an antidote for intracranial bleeding in patients taking direct factor Xa inhibitors. World Neurosurg. 2015; 84:1956-61.
92. Messana E, Wilson SS. Activated PCC (FEIBA) for reversal of rivaroxaban-induced life-threatening bleeding - a case series. Crit Care Med. 2015; 43:303. Abstract.
93. Lam WW, Reyes MA, Seger JJ. Plasma exchange for urgent apixaban reversal in a case of hemorrhagic tamponade after pacemaker implantation. Tex Heart Inst J. 2015; 42:377-80.
94. Sienko S, Vasovski M, Ali M. Evaluation of activated prothrombin complex concentrate use and its role in the reversal of novel oral anticoagulants. J Thromb Haemost. 2015; 13:880. Abstract.
95. Baker R, Gallus A, Brighton T et al. Treatment options for major haemorrhage and urgent intervention in patients on a NOAC - interim results from the anticoagulation reversal and events study (ARES) collaborative. J Thromb Haemost. 2015; 13:643.
96. Wong H, Keeling D. Activated prothrombin complex concentrate for the prevention of dabigatranassociated bleeding. Br J Haematol. 2014; 166:152-3.
97. Shaw J, Le Gal G, Tokessy M et al. FEIBA for patients on direct oral anticoagulants requiring urgent surgery. Blood. 2014; 124:4259.
98. Kohler M, Hellstern P, Lechler E et al. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb Haemost. 1998; 80:399-402.
99. Pabinger I, Brenner B, Kalina U et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008; 6:622-31.
100. Willis CM, Hall AB. Use of fourfactor prothrombin complex concentrate in the emergency department: a review. J Emerg Nurs. 2015; 41:9-12.
101. Castellucci LA, Shaw J, Le Gal G et al. Use of prothrombin complex concentrate and activated prothrombin complex concentrate for reversal of direct oral anticoagulant associated bleeding. J Thromb Haemost. 2015; 13:623. Abstract.
102. Smythe MA, Trujillo T, Fanikos J. Reversal agents for use with direct and indirect oral anticoagulants. Am J Health-Syst Pharm. 2016; 73(suppl 2):S27-48.
103. Boehringer Ingelheim. Praxbind (idarucizumab) prescribing information. www.accessdata.fda.gov/drugsatfda-docs/ label/2015/761025lbl.pdf (accessed 2015 Oct 20).
104. Portola Pharmaceuticals. Portola Pharmaceuticals receives FDA orphan drug designation for andexanet alfa, its breakthroughdesignated factor Xa inhibitor antidote. http://investors.portola.com/ phoenix.zhtml?c=198136&p=irolnewsroomArticle&ID=2020507 (accessed 2015 Aug 12).
105. Perosphere. Perosphere receives FDA fast track designation for investigational anticoagulant reversal agent PER977. http:// perosphere.com/documents/ PerosphereFDAFastTrack.pdf (accessed 2015 Aug 12).
106. Pollack CV Jr, Reilly PA, Eikelboom J et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015; 373:511-20.
107. Stangier J, Schmohl M, Glund S et al. Idarucizumab does not have prothrombotic effects: assessment of coagulation markers in healthy volunteers. J Thromb Haemost. 2015; 13(suppl 2):217.
108. Shakur H, Roberts I, Bautista R et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010; 376:23-32.